jrnls.org logo
Submit

BROWSE ALL JOURNALS

Type 2 letters to search all 19 journals

SEE ALL 19 JOURNALS
Journal of Pharmacology and PharmacotherapeuticsNOW IN
Back

JPP · Lens · Is a Glucocorticoid Antagonist a Potential Treatment Alternative for Antipsychotic‑Induced Weight Gain?

PDF

Article · Volume 12, Issue 2 · pp. 37–41

Is a Glucocorticoid Antagonist a Potential Treatment Alternative for Antipsychotic‑Induced Weight Gain?

Wisam Al Jumaili1, Chintan Trivedi2, Kaushal Shah3, Mahwish Adnan4, Zeeshan Mansuri5, Shailesh Jain6

  1. 1Northwest Clinical Research Center, Bellevue, Washington, USA.
  2. 2St. David Medical Center, Austin, TX, USA.
  3. 3Department of Psychiatry, Griffin Memorial Hospital, Norman, and Oklahoma State University, Tulsa, Oklahoma, USA.
  4. 4Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
  5. 5Department of Psychiatry, Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, USA.
  6. 6Department of Psychiatry, Texas Tech University Health Science Center at Odessa/Permian Basin, Odessa, Texas, USA.

Abstract

Objective: To evaluate the efficacy and safety of mifepristone as a new treatment modality for antipsychotic-induced weight gain.Methods: We searched databases up to March 2021, for the published English‑language literature including a Medical Subject Heading “Mifepristone,” “Receptors, Glucocorticoid,” “Weight gain,” “Overweight,” “Obesity,” “Body Weight Change,” “Antipsychotics Agents,” “Glucocorticoid Receptor Blocker,” “Glucocorticoid Receptor antagonist.” We identified two clinical and four preclinical studies utilizing mifepristone as a treatment modality.Results: The results of the olanzapine clinical trial showed that mean increase in weight from baseline to day 14 was greater in the olanzapine with the placebo group (3.2 ± 0.9 kg) than the olanzapine with mifepristone group (2.0 ± 1.2 kg) and the mifepristone with placebo (2.0 ± 0.7 kg), and a similar effect was observed in the risperidone with mifepristone clinical trial.Conclusions: Mifepristone shows potential in the management of AIWG. Glucocorticoid antagonists can be a viable alternative to curb this side effect. Large‑scale clinical studies are warranted to determine the medication’s safety and efficacy based on this mechanism of action.

Keywords: Antipsychotics; obesity; olanzapine

The full text of this article is available as a PDF. Open the PDF.